Research & Development

Recordati continuously develops new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes.

 

Commitment, scientific rigour, capability and highly specialized personnel allow the Group to develop new treatments and to build an innovative product pipeline.

Life Cycle Management
New Products
Post Marketing

In addition to the above, RRD is conduding Rollover studies for Signifor and Isturisa as well as several safety commitments, among which
PASS for Cystadrops, Isturisa, Signifor, Qarziba, and Carbaglu PA/MMA, iMO (Castleman’s Disease) Registries

NAME
ORIGINATOR
INDICATION
DEVELOPMENT STATUS
ELIGARD®
Tolmar
Hormone-dependent prostate cancer
New device post-approval activities
ISTURISA®
Novartis
Endogenous Cushing’s syndrome/Cushing’s disease
Approved in the USA, Europe, Switzerland, Australia, Israel and Japan. Filed in other countries
SIGNIFOR®
Novartis
Pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
Phase II in progress
CYSTADROPS®
Recordati
Corneal cystine crystal deposits in patients with cystinosis
Approved in the USA and Europe. Development of new formulations in the USA and EU
QARZIBA®
Apeiron/Recordati
Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma
Approved in the EU, UK, Australia, Brazil, China Hong Kong, Israel, Russia and Taiwan. Under development for registration in other territories, including USA and Switzerland
SYLVANT®
Recordati
Treatment of idiopathic Multicentric Castleman Disease (iMCD)
Approved in over 40 countries including EU, US and China. Potential indication expansion evaluation ongoing
REC 0559
Recordati/M1meTech
Neurotrophic keratitis
Phase 2 in progress
REC 0545
Recordati/AP-HP
Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosis
Filing expected in 2023
CARBAGLU®
(Recordati RareDiseases)
Hyperammonaemia due to NAGS deficiency and to the main organic acidaemias
Regulatory procedure ongoing in China for approval in NAGS deficiency and organic acidaemias
REAGILA®
Gedeon Richter
Schizophrenia
Paediatric post-approval development plan

We are uniquely structured with multiple opportunities across our R&D team including CMC, preclinical, regulatory, patient safety, QA, clinical operations, clinical development, medical affairs. We are continuously growing, with a focus on developing new specialties, new treatments – and investing in medical innovations that bring a brighter future.

Interested in joining our team?

We foster an entrepreneurial environment where high-performing individuals are empowered to make a difference across our organisation.

Read More

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.